Granted Patent
B2
US 12,458,695 · App. 19/054,696 · Granted Nov 4, 2025
Dosing regimens and related compositions and methods
Inventors:
Federico Grossi (Needham, MA); Pascal Deschatelets (West Newton, MA); Cedric Francois (Prospect, KY); Patrick Johnson (Zurich, CH); Carolina Vega (Berkeley, CA)
Assignee:
Apellis Pharmaceuticals, Inc.
A61K39/3955A61K9/0019A61K38/10A61K38/12A61K47/183A61K47/26A61K47/54A61K47/542A61P7/06A61P27/02C07K7/08
View Patent ↗
Loading inventors, assignments & file history…
Abstract
In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.
Claims (40)
1 . A composition comprising:
(i) a long-acting compstatin analog (LACA) having a structure:
wherein the (CH 2 CH 2 O) n moiety has an average molecular weight of about 40,000 Daltons;
(ii) a pharmaceutically acceptable carrier; and
(iii) trehalose,
wherein the pH of the composition is 4.9 to 5.1.
2 . The composition of claim 1 , wherein the LACA is at a concentration of about 150 mg/mL.
3 . The composition of claim 2 , wherein the composition has an osmolality between 180 mOsm/kg and 500 mOsm/kg.
4 . The composition of claim 3 , wherein the composition comprises an acetate buffer.
5 . The composition of claim 4 , wherein the acetate buffer comprises sodium acetate and acetic acid.
6 . The composition of claim 5 , wherein the pharmaceutically acceptable carrier is water.
7 . The composition of claim 6 , wherein the pH of the composition is 5.0.
8 . A single dose vial containing the composition of claim 6 for delivery of a 100 microliter dose of said composition.
9 . The composition of claim 2 , wherein the composition has an osmolality between 200 mOsm/kg and 400 mOsm/kg.
10 . The composition of claim 9 , wherein the composition comprises an acetate buffer.
11 . The composition of claim 10 , wherein the acetate buffer comprises sodium acetate and acetic acid.
12 . The composition of claim 1 , wherein the pharmaceutically acceptable carrier is water.
13 . The composition of claim 1 , consisting essentially of the LACA, trehalose, acetate buffer, and water.
14 . The composition of claim 13 , wherein the acetate buffer comprises sodium acetate and acetic acid.
15 . The composition of claim 13 , wherein the LACA is at a concentration of about 150 mg/mL and the composition has an osmolality between 180 mOsm/kg and 500 mOsm/kg.
16 . The composition of claim 15 , wherein the pH of the composition is 5.0.
17 . A single dose vial containing the composition of claim 15 , for delivery of a 100 microliter dose of said composition.
18 . The composition of claim 15 , wherein the LACA is at a concentration of about 150 mg/mL and the composition has an osmolality between 200 mOsm/kg and 400 mOsm/kg.
19 . A composition comprising:
(i) a long-acting compstatin analog (LACA) having a structure:
wherein the (CH 2 CH 2 O) n moiety has an average molecular weight of about 40,000 Daltons;
(ii) a pharmaceutically acceptable carrier; and
(iii) trehalose,
wherein the pH of the composition is 4.5 to 5.0.
20 . The composition of claim 19 , wherein the LACA is at a concentration of about 150 mg/mL.
21 . The composition of claim 20 , wherein the composition has an osmolality between 180 mOsm/kg and 500 mOsm/kg.
22 . The composition of claim 21 , wherein the composition comprises an acetate buffer.
23 . The composition of claim 20 , wherein the composition has an osmolality between 200 mOsm/kg and 400 mOsm/kg.
24 . The composition of claim 23 , wherein the composition comprises an acetate buffer.
25 . The composition of claim 24 , wherein the pharmaceutically acceptable carrier is water.
26 . The composition of claim 19 , consisting essentially of the LACA, trehalose, acetate buffer, and water.
27 . The composition of claim 26 , wherein the acetate buffer comprises sodium acetate and acetic acid.
28 . The composition of claim 26 , wherein the LACA is at a concentration of about 150 mg/mL and the composition has an osmolality between 180 mOsm/kg and 500 mOsm/kg.
29 . A single dose vial containing the composition of claim 28 , for delivery of a 100 microliter dose of said composition.
30 . The composition of claim 19 , wherein the pH of the composition is 4.5.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 6, 2025
From: GROSSI, FEDERICO; DESCHATELETS, PASCAL; FRANCOIS, CEDRIC; VEGA, CAROLINA
To: APELLIS PHARMACEUTICALS, INC.
Reel/Frame 070429/0837 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 6, 2025
From: JOHNSON, PATRICK
To: JPHARMA SOLUTIONS GMBH
Reel/Frame 070429/0901 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 6, 2025
From: JPHARMA SOLUTIONS GMBH
To: APELLIS PHARMACEUTICALS, INC.
Reel/Frame 070429/0907 →
Continuity (6)
Continuation
16772729
Provisional Application
62744565
· Oct 11, 2018
Provisional Application
62655094
· Apr 9, 2018
Provisional Application
62599637
· Dec 15, 2017
References Cited (400)
US 4299838A
· Durlach
· 1981
[cited by applicant]
US 4576750A
· Pitzenberger
· 1986
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 4870097A
· Makovec et al.
· 1989
[cited by applicant]
US 5157110A
· Kotwal et al.
· 1992
[cited by applicant]
US 5482135A
· Phillips et al.
· 1996
[cited by applicant]
US 5492135A
· Hubbell
· 1996
[cited by applicant]
US 5632984A
· Wong et al.
· 1997
[cited by applicant]
US 5770589A
· Billson et al.
· 1998
[cited by applicant]
US 5776970A
· Shechter et al.
· 1998
[cited by applicant]
US 5797898A
· Santini, Jr. et al.
· 1998
[cited by applicant]
US 5824072A
· Wong
· 1998
[cited by applicant]
US 5844099A
· Stahl et al.
· 1998
[cited by applicant]
US 5861486A
· Devore et al.
· 1999
[cited by applicant]
US 5869079A
· Wong et al.
· 1999
[cited by applicant]
US 5942405A
· Ames et al.
· 1999
[cited by applicant]
US 6051698A
· Janjic et al.
· 2000
[cited by applicant]
US 6129761A
· Hubbell
· 2000
[cited by applicant]
US 6140472A
· Rosengard et al.
· 2000
[cited by applicant]
US 6169057B1
· Lovatt
· 2001
[cited by applicant]
US 6197934B1
· DeVore et al.
· 2001
[cited by applicant]
US 6204365B1
· Devore et al.
· 2001
[cited by applicant]
US 6214790B1
· Richelson et al.
· 2001
[cited by applicant]
US 6319897B1
· Lambris et al.
· 2001
[cited by applicant]
US 6331313B1
· Wong et al.
· 2001
[cited by applicant]
US 6378526B1
· Bowman et al.
· 2002
[cited by applicant]
US 6436427B1
· Hammang et al.
· 2002
[cited by applicant]
US 6534058B2
· Fung et al.
· 2003
[cited by applicant]
US 6551595B1
· Rosengard et al.
· 2003
[cited by applicant]
US 6582959B2
· Kim
· 2003
[cited by applicant]
US 6692759B1
· Wong et al.
· 2004
[cited by applicant]
US 6818447B1
· Pavco et al.
· 2004
[cited by applicant]
US 6821950B1
· Fairlie et al.
· 2004
[cited by applicant]
US 6897290B1
· Atkinson et al.
· 2005
[cited by applicant]
US 6976982B2
· Santini, Jr. et al.
· 2005
[cited by applicant]
US 7084106B1
· Kotwal et al.
· 2006
[cited by applicant]
US 7108982B1
· Hageman
· 2006
[cited by applicant]
US 7112327B2
· Fung et al.
· 2006
[cited by applicant]
US 7745389B2
· Hageman
· 2010
[cited by applicant]
US 7888323B2
· Lambris et al.
· 2011
[cited by applicant]
US 7947267B2
· Francois et al.
· 2011
[cited by applicant]
US 7989589B2
· Lambris
· 2011
[cited by applicant]
US 8043609B2
· Deschatelets et al.
· 2011
[cited by applicant]
US 8168584B2
· Deschatelets et al.
· 2012
[cited by applicant]
US 8521273B2
· Kliman
· 2013
[cited by applicant]
US 8580735B2
· Francois et al.
· 2013
[cited by applicant]
US 8753625B2
· Fung et al.
· 2014
[cited by applicant]
US 8840893B2
· Schwaeble et al.
· 2014
[cited by applicant]
US 8871230B2
· Rudolph et al.
· 2014
[cited by applicant]
US 9056076B2
· Deschatelets et al.
· 2015
[cited by applicant]
US 9107861B1
· Andrien, Jr. et al.
· 2015
[cited by applicant]
US 9421240B2
· Francois et al.
· 2016
[cited by applicant]
US 9512180B2
· Morikis et al.
· 2016
[cited by applicant]
US 20020086356A1
· Tuschl et al.
· 2002
[cited by applicant]
US 20020102581A1
· Hageman et al.
· 2002
[cited by applicant]
US 20030171320A1
· Guyer
· 2003
[cited by applicant]
US 20030175950A1
· McSwiggen
· 2003
[cited by applicant]
US 20030191084A1
· Biesecker et al.
· 2003
[cited by applicant]
US 20040038869A1
· Finney et al.
· 2004
[cited by applicant]
US 20040087513A1
· Duettmann et al.
· 2004
[cited by applicant]
US 20040092470A1
· Leonard et al.
· 2004
[cited by applicant]
US 20050020525A1
· McSwiggen et al.
· 2005
[cited by applicant]
US 20050032733A1
· McSwiggen et al.
· 2005
[cited by applicant]
US 20050048099A1
· Shiah et al.
· 2005
[cited by applicant]
US 20050054596A1
· McSwiggen et al.
· 2005
[cited by applicant]
US 20050244469A1
· Whitcup et al.
· 2005
[cited by applicant]
US 20050244472A1
· Hughes et al.
· 2005
[cited by applicant]
US 20050255144A1
· Schultz
· 2005
[cited by applicant]
US 20050281861A1
· Hughes et al.
· 2005
[cited by applicant]
US 20060140939A1
· Fung
· 2006
[cited by applicant]
US 20060257359A1
· Francois et al.
· 2006
[cited by applicant]
US 20060263819A1
· Hageman et al.
· 2006
[cited by applicant]
US 20070065433A1
· Mollnes et al.
· 2007
[cited by applicant]
US 20070134244A1
· Slakter et al.
· 2007
[cited by applicant]
US 20070149616A1
· Clark et al.
· 2007
[cited by applicant]
US 20070196367A1
· Dinu
· 2007
[cited by applicant]
US 20070293873A1
· Chang
· 2007
[cited by applicant]
US 20090220572A1
· Deschatelets et al.
· 2009
[cited by applicant]
US 20110092446A1
· Francois et al.
· 2011
[cited by applicant]
US 20110182877A1
· Francois et al.
· 2011
[cited by applicant]
US 20130011378A1
· Yang et al.
· 2013
[cited by applicant]
US 20130072442A1
· Deschatelets et al.
· 2013
[cited by applicant]
US 20130324482A1
· Francois et al.
· 2013
[cited by applicant]
US 20140050739A1
· Francois et al.
· 2014
[cited by applicant]
US 20140113874A1
· Lambris et al.
· 2014
[cited by applicant]
US 20150064176A1
· Schwaeble et al.
· 2015
[cited by applicant]
US 20160015810A1
· Deschatelets et al.
· 2016
[cited by applicant]
US 20160060297A1
· Deschatelets et al.
· 2016
[cited by applicant]
US 20160067357A1
· Francois et al.
· 2016
[cited by applicant]
US 20160194359A1
· Francois et al.
· 2016
[cited by applicant]
US 20170283461A1
· Francois et al.
· 2017
[cited by applicant]
US 20200316163A1
· Grossi et al.
· 2020
[cited by applicant]
US 20200325175A1
· Francois et al.
· 2020
[cited by applicant]
US 20240285783A1
· Grossi et al.
· 2024
[cited by applicant]
US 20250170210A1
· Grossi et al.
· 2025
[cited by applicant]
BR 112013028816A2
· 2016
[cited by applicant]
BR 112018006810A2
· 2018
[cited by applicant]
BR 112019007613A2
· 2019
[cited by applicant]
EP 0422681A1
· 1991
[cited by applicant]
EP 0737484A2
· 1996
[cited by applicant]
EP 2278987A2
· 2011
[cited by applicant]
EP 2311479A1
· 2011
[cited by applicant]
EP 2662089A2
· 2013
[cited by applicant]
EP 1993673B1
· 2017
[cited by applicant]
JP 11197234A
· 1999
[cited by applicant]
JP 2003535581A
· 2003
[cited by applicant]
JP 2004065461A
· 2004
[cited by applicant]
JP 2006505254A
· 2006
[cited by applicant]
JP 2009511496A
· 2009
[cited by applicant]
JP 2009517476A
· 2009
[cited by applicant]
JP 2010280688A
· 2010
[cited by applicant]
JP 2010540654A
· 2010
[cited by applicant]
JP 2012525443A
· 2012
[cited by applicant]
JP 2015523999A
· 2015
[cited by applicant]
JP 2016505527A
· 2016
[cited by applicant]
MX 2018004243A
· 2018
[cited by applicant]
RU 2474586C2
· 2013
[cited by applicant]
RU 2505311C2
· 2014
[cited by applicant]
RU 2013149956A
· 2015
[cited by applicant]
WO WO96030046A1
· 1996
[cited by applicant]
WO WO9733603A1
· 1997
[cited by applicant]
WO WO99013899A1
· 1999
[cited by applicant]
WO WO0047130A1
· 2000
[cited by applicant]
WO WO0071147A1
· 2000
[cited by applicant]
WO WO0184149A2
· 2001
[cited by applicant]
WO WO2002011793A1
· 2002
[cited by applicant]
WO WO2003047633A2
· 2003
[cited by applicant]
WO WO2003086448A1
· 2003
[cited by applicant]
WO WO2004026328A1
· 2004
[cited by applicant]
WO WO2004028635A1
· 2004
[cited by applicant]
WO WO2004037310A2
· 2004
[cited by applicant]
WO WO2004041160A2
· 2004
[cited by applicant]
WO WO2005023296A1
· 2005
[cited by applicant]
WO WO2005110435A1
· 2005
[cited by applicant]
WO WO2005110436A2
· 2005
[cited by applicant]
WO WO2006042329A2
· 2006
[cited by applicant]
WO WO2006062716A2
· 2006
[cited by applicant]
WO WO2006080951A2
· 2006
[cited by applicant]
WO WO2006099330A2
· 2006
[cited by applicant]
WO WO2006119767A3
· 2007
[cited by applicant]
WO WO2007044668A2
· 2007
[cited by applicant]
WO WO2007056227A2
· 2007
[cited by applicant]
WO WO2007076437A2
· 2007
[cited by applicant]
WO WO2007084765A2
· 2007
[cited by applicant]
WO WO2007062249A2
· 2007
[cited by applicant]
WO WO2009015087A2
· 2009
[cited by applicant]
WO WO2009046198A2
· 2009
[cited by applicant]
WO WO2010127336A1
· 2010
[cited by applicant]
WO WO2010135717A2
· 2010
[cited by applicant]
WO WO2011076391A1
· 2011
[cited by applicant]
WO WO2011163394A2
· 2011
[cited by applicant]
WO WO2012006599A2
· 2012
[cited by applicant]
WO WO2012040259A2
· 2012
[cited by applicant]
WO WO2012155107A1
· 2012
[cited by applicant]
WO WO2012178083A1
· 2012
[cited by applicant]
WO WO2013036778A2
· 2013
[cited by applicant]
WO WO2013192319A1
· 2013
[cited by applicant]
WO WO2014078731A2
· 2014
[cited by applicant]
WO WO2014078734A2
· 2014
[cited by applicant]
WO WO2014078731A3
· 2014
[cited by applicant]
WO WO2014102596A2
· 2014
[cited by applicant]
WO WO2014152391A1
· 2014
[cited by applicant]
WO WO2015142701A1
· 2015
[cited by applicant]
WO WO2016049385A1
· 2016
[cited by applicant]
WO WO2016172712A2
· 2016
[cited by applicant]
WO WO2017062879A2
· 2017
[cited by applicant]
WO WO2018075373A1
· 2018
[cited by applicant]
WO WO2018187813A1
· 2018
[cited by applicant]
WO WO2019118938A1
· 2019
[cited by applicant]
Heier et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. The Lancet,…
[cited by examiner]
Center for Drug Evaluation and Research, FDA. Application No. 217171Orig1s000, Clinical Pharmacology Reviews. Feb. 17, 2023. Retrieved from the internet on May 2, 2025, from <https://www.accessdata.fda.gov/drugsatfda_do…
[cited by examiner]
ClinicalTrials.gov ID NCT03525600. published May 15, 2018. Retrieved from the internet May 2, 2025, from <https://www.clinicaltrials.gov/study/NCT03525600?term=Pegcetacoplan&sort=StudyFirstPostDate&cond=Eye%20Diseases&r…
[cited by examiner]
ClincalTrials.gov ID NCT03525613, published May 15, 2018. Retreived from the Internet May 2, 2025, from <https://www.clinicaltrials.gov/study/NCT03525613?term=Pegcetacoplan&sort=StudyFirstPostDate&cond=Eye%20Diseases&ra…
[cited by examiner]
EMPAVELI™ (pegcetacoplan) injection, for subcutaneous use. Published May 14, 2021. Retrieved from the internet on May 2, 2025, from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215014s000lbl.pdf>. 22 pages…
[cited by examiner]
Acosta, J. et al., Complement and complement regulatory proteins as potential molecular targets for vascular diseases, Curr. Pharm. Des., 10(2):203-11 (2004).
[cited by applicant]
Acosta, J. et al., Molecular basis for a link between complement and the vascular complications of diabetes, Proc. Nat. Acad. Sci., 97(10):5450 (2000).
[cited by applicant]
Albrecht, J.C. and Fleckenstein, B., New Member of the Multigene Family of Complement Control Proteins in Herpes Saimiri, Journal of Virology, 66(6):3937-3940 (1992).
[cited by applicant]
Albrecht, J.C. et al., Herpesvirus Saimiri Has a Gene Specifying a Homologue of the Cellular Membrane Glycoprotein CD59, Virology, 190(1):527-530 (1992).
[cited by applicant]
Aldrich, ChemFiles, Peptide Synthesis, 7(2): 20 pages (2007).
[cited by applicant]
Allen, T.M., Ligand-Targeted Therapeutics in Anticancer Therapy, Nature Reviews Cancer, 2(10):750-765 (2002).
[cited by applicant]
Altschul, S.F. et al., Basic local alignment search tool, Journal of Molecular Biology, 215(3):403-410 (1990).
[cited by applicant]
Altschul, S.F., Gapped BLAST and PSI-BLAST: a New Generation of Protein Database Search Programs, Nucleic Acids Research, 25(17):3389-3402 (1997).
[cited by applicant]
Ambati, J. et al., Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies, Survey of Ophthalmology, 48(3):257-293 (2003).
[cited by applicant]
Ambati, J. et al., An Animal Model of Age-Related Macular Degeneration in Senescent Ccl-2- or Ccr-2-Deficient Mice, Nature Medicine, 9(11):1390-1397 (2003).
[cited by applicant]
American Academy of Ophthalmology, Age-Related Macular Degeneration, Preferred Practice Pattern, American Academy of Ophthalmology, San Francisco, CA (2006).
[cited by applicant]
Anderson, Amy C., The Process of Structure-Based Drug Design, Chemistry & Biology, 10:787-797 (2003).
[cited by applicant]
Anderson, DH, et al., A role for local inflammation in the formation of drusen in the aging eye, Am. J. Ophthalmol, 134: 411-431 (2002).
[cited by applicant]
Author Not Known, Peptide User Guide: A brief introduction into synthesis methods, handling and design of peptides, Bachem Brochure, 24 pages (2009).
[cited by applicant]
Babitzke, P. and Yanofsky, C., Structural Features of L-Tryptophan Required for Activation of TRAP, the trp RNA-Binding Attenuation Protein of Bacillus subtilis, Journal of Biological Chemistry, 270(21):12452-12456 (199…
[cited by applicant]
Barlett, J.B. et al., The Evolution of Thalidomide and its IMiD Derivatives as Anticancer Agents, Nature Reviews Cancer, 4 (4):314-322 (2004).
[cited by applicant]
Bartz, R. et al., Effective siRNA delivery and target mRNA degradation using an amphipathic peptide to facilitate pH-dependent endosomal escape, Biochem J., 435:475-487 (2011).
[cited by applicant]
BD, Subcutaneous Injection Guidelines for Needle Length and Gauge Selection, available from www.bd.com, 2 pages (2012).
[cited by applicant]
Beene, D.L. et al., Cation-π Interactions in Ligand Recognition by Serotonergic (5-HT3A) and Nicotinic Acetylcholine Receptors: The Anomalous Binding Properties of Nicotine, Biochemistry, 41(32):10262-10269 (2002).
[cited by applicant]
Bora, P.S. et al., Immunotherapy for Choroidal Neovascularization in a Laser-Induced Mouse Model Simulating Exudative (Wet) Macular Degeneration, Proceedings of the National Academy of Science, 100(5):2679-2684 (2003).
[cited by applicant]
Bora, PS et al., Complement activation by alternative pathway is critical in the development of laser-induced choroidal neovascularization, Invest Ophthalmol Vis Sci, 47: E-Abstract 4167 (2006).
[cited by applicant]
Bora, PS et al., Neovascularization in a mouse model that simulates exudative macular degeneration is complement dependent, Invest. Ophthalmol. Vis. Sci. 45: E-Abstract 1871 (2004).
[cited by applicant]
Bora, PS et al., Role of complement and complement membrane attack complex in neovascularization, Journal of Immunology, 174 (1): 491-497 (2005).
[cited by applicant]
Bora, PS, et al., Complement Activation is Required in the Murine Model of Laser-induced Choroidal Neovascularization, Invest. Ophthalmol. Vis. Sci., 44: E-Abstract 3940 (2003).
[cited by applicant]
Bourges, J-L. et al., Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles, Investigative Ophthalmology and Visual Sciences, 44(8):3562-3569 (2003).
[cited by applicant]
Braun, J., UCSB Studies Link Alzheimer's Disease, Macular Degeneration, The Daily Nexus, University of California, Santa Barbara, 83(135): 1-5 (Published May 28, 2003).
[cited by applicant]
Chapple, J.P. et al., Unfolding retinal dystrophies: a role for molecular chaperones?, Trends in Mol. Med., 7: 414-421 (2001).
[cited by applicant]
Charkravarthy, U. et al., Year 2 Efficacy Results of 2 Randomized Controlled Clinical Trials of Pegaptanib for Neovascular Age-Related Macular Degeneration, Ophthalmology, 113:1508-1521 (2006).
[cited by applicant]
Chauhan, A. et al., The Taming of the Cell Penetrating Domain of the HIV Tat: Myths and Realities, J. Control Release, 117(2):148-162 (2007).
[cited by applicant]
ChemIDplus record for Pegcetacoplan, available from chem.nim.nih.gov/chemidplus/m/2019171-69-6, 2 pages (2019).
[cited by applicant]
Clinical Trial NCT02461771, posted Jun. 3, 2015, downloaded from clinicaltrials.gov, 3 pages (2015).
[cited by applicant]
Clinical Trial NCT02503332, available from clinicaltrials.gov on Jul. 17, 2015, 3 pages.
[cited by applicant]
Conley YP, et al., Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy, Hum. Mol. Genet., 14:1991-2002 (2005).
[cited by applicant]
Corrales, L. et al., Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression, The Journal of Immunology, 4674-4683 (2012).
[cited by applicant]
D'Amico, D. et al., Pegaptanib Sodium for Neovascular Age-Related Macular Degeneration, Ophthalmology, 113:992-1001 (2006).
[cited by applicant]
Database BIOSIS on STN, BIOSIS, (Philadelphia, PA, USA), DN: PREV200600053073, & Raisler, B.J. et al., Drusen Complement Components C3a and C5a Promote Choroidal Neovascularization, IOVS, 2005, vol. 46, No. Suppl, p. 12…
[cited by applicant]
Davenport, R.J., Tarnished Vision, Sci. Aging Knowl. Environ., 2004(37): nf85 (2004).
[cited by applicant]
Debets, M. et al., Aza-dibenzocyclooctynes for fast and efficient enzyme PEGylation via copper-free (3 + 2) cycloaddition, Chem. Commun., 46:97-99 (2010).
[cited by applicant]
Deshayes, S. et al., Cell-penetrating peptides: tools for intracellular delivery of therapeutics, CMLS Cellular and Molecular Life Sciences, 62:1839-1849 (2005).
[cited by applicant]
Donoso, L. et al., The role of inflammation in the pathogenesis of age-related macular degeneration, Survey of Ophthalmology, 51(2):137-152 (2006).
[cited by applicant]
Edwards, AO et al., Complement Factor H Polymorphism and Age-Related Macular Degeneration, Science, 308(5720):421-424 (2005).
[cited by applicant]
Eguchi, M. and Kahn, M., Design, Synthesis, and Application of Peptide Secondary Structure Mimetics, Mini Reviews in Medicinal Chemistry, 2(5):447-462 (2002).
[cited by applicant]
Einmahl, S. et al., Evaluation of a Novel Biomaterial in the Suprachoroidal Space of the Rabbit Eye, Investigative Ophthalmology and Visual Science, 43(5):1533-1539 (2002).
[cited by applicant]
Ferrara, N., Vascular Endothelial Growth Factor: Basic Science and Clinical Progress, Endocrine Reviews, 25(4):581-611 (2004).
[cited by applicant]
Fish et al., Anti-vascular Endothelial Growth Factor Therapy for Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration, Phase II Study Results, The Eyetech Study Group, Ophthalmology, 110:…
[cited by applicant]
Frankel, A. et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng, 13(8):575-81 (2000).
[cited by applicant]
Fung, A.E. et al., An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration, Am. J. Ophthalmol., 143:566-583 (2007).
[cited by applicant]
Futaki, S. et al., An Abundant Source of Membrane-Permeable Peptides Having Potential as Carriers for Intracellular Protein Delivery, The Journal of Biological Chemistry, 276(8):5836-5840 (2001).
[cited by applicant]
Gaudreault, J. et al., Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration, Investigative Ophthalmology and Visual Science, 46(2):726-733 (2005).
[cited by applicant]
Gautam, A. et al., CPPsite: a curated database of cell penetrating peptides, Database, 7 pages (2012).
[cited by applicant]
George, G.A. and Goss, B., Elastomers in Oxygen and Ozone, Degradation of Reference Module in Materials Science and Materials Engineering, 6 pages (2016).
[cited by applicant]
Gerl, V et al., Extensive Deposits of Complement C3d and C5b-9 in the Choriocapillaris of Eyes of Patients with Diabetic Retinopathy, Investigative Ophthalmology and Visual Sciences, 43(4):1104-1108 (2002).
[cited by applicant]
Gold, B. et al., Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration, Nature Genetics, 38: 458-462 (2006).
[cited by applicant]
Gonzales, N.R. et al., Minimizing the Immunogenicity of Antibodies for Clinical Application, Tumour Biology, 26(1):31-43 (2005).
[cited by applicant]
Gragoudas et al., Pegaptanib for Neovascular Age-Related Macular Degeneration, NE J Med., 351(27):2805-2816 (2004).
[cited by applicant]
Haas, A. K. et al., Human protein derived peptides for intracellular delivery of biomolecules, Biochemical Journal Immediate Publication, 25 pages (2011).
[cited by applicant]
Hageman, GS et al., A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration, Proceedings of the National Academy of Sciences, 102(20):7053-7054…
[cited by applicant]
Hageman, GS et al., An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration, Progress in Retinal and …
[cited by applicant]
Haines, JL et al., Complement factor H variant increases the risk of age-related macular degeneration, Science, 308(5720):419-421 (2005).
[cited by applicant]
Hanes, J. and Pluckthun, A., In Vitro Selection and Evolution of Functional Proteins by Using Ribosome Display, Proceedings of the National Academy of Science, 94(10):4937-4947 (1997).
[cited by applicant]
Ho, A. et al., Synthetic Protein Transduction Domains: Enhanced Transduction Potential in Vitro and in Vivo, Cancer Research, 61:474-477 (2001).
[cited by applicant]
Holland, MCH, et al., Synthetic small-molecule complement inhibitors, Curr. Op. Invest. Drugs, 5(11) 1164-1173 (2004).
[cited by applicant]
Hrynchak, PK, et al., Optical coherence tomography: an introduction to the technique and its use, Optometry and Vision Science, 77(7): 347-356 (2000).
[cited by applicant]
Hughes et al., A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration, Nature Genetics, 38(10):1173-1177 (2006).
[cited by applicant]
International Search Report for PCT/US05/036547, 5 pages (Jun. 10, 2006).
[cited by applicant]
International Search Report for PCT/US06/039397, 6 pages (Oct. 24, 2007).
[cited by applicant]
International Search Report for PCT/US18/65870 (Dosing Regimens and Related Compositions and Methods, filed Dec. 14, 2018), issued by ISA/US, 7 pages (May 17, 2019).
[cited by applicant]
International Search Report for PCT/US2012/037648, (Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof, filed May 11, 2012) issued by ISA, 3 pages (received Sep. 20, 2012).
[cited by applicant]
International Search Report for PCT/US2013/070417, 3 pages (Jun. 5, 2014).
[cited by applicant]
International Search Report for PCT/US2013/070424, 3 pages (Jun. 5, 2014).
[cited by applicant]
International Search Report for PCT/US2014/27289, 4 pages (Aug. 19, 2014).
[cited by applicant]
International Search Report for PCT/US2016/56144, 6 pages (Apr. 27, 2017).
[cited by applicant]
International Search Report for PCT/US2018/026753 (Dosing Regimens and Related Compositions and Methods, filed Apr. 9, 2018), issued by ISA/US, 6 pages (Sep. 13, 2018).
[cited by applicant]
International Search Report from PCT/US2007/001649 (Mar. 31, 2008).
[cited by applicant]
Internet Citation: URL: www.rsinewsrxreportingfrom.com/ content.asp?myid+40&tid=365> Anti-VEGF Agents Useful in Age-Related Macular Degeneration, Am Acad of Ophthalm, (Oct. 15, 2005).
[cited by applicant]
Ishida, T. et al., A Combinational Approach to Producing Sterically Stabilized (Stealth) Immunoliposomal Drugs, FEBS Letters, 460(1):129-133 (1999).
[cited by applicant]
Jaffe, G. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device, Investigative Ophthalmology and Visual Sciences, 41(11):3569-3575 (2000).
[cited by applicant]
Jager et al., Age-related Macular Degeneration, N. Engl. J. Med., 358(24): 2606-2617 (2008).
[cited by applicant]
Jha, P. et al., The complement system plays a critical role in the development of experimental autoimmune anterior uveitis, Investigative Ophthalmology and Visual Sciences, 47(3):1030-1038 (2006).
[cited by applicant]
Johnson, L.V. et al., Complement activation and inflammatory processes in drusen formation and age-related macular degeneration, Experimental Eye Research, 73(6):887-896, Academic Press Ltd., London, GB (2001).
[cited by applicant]
Kabouridis, Panagiotis S., Biological applications of protein transduction technology, Trends Biotechnol., 21(11):498-503 (2003).
[cited by applicant]
Kalayoglu, M.V., Emerging Treatment Strategies for Age-related Macular Degeneration, Internet Citation, URL: <www.medcompare.com/spotlight.asp?spotlightid=62> (Retrieved Jun. 30, 2004).
[cited by applicant]
Karlin, S. and Altschul, S.F., Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences, Proceedings of the National Academy of Science, 90(12):5873-5877 (1993).
[cited by applicant]
Karlin, S. and Altschul, S.F., Methods for Assessing the Statistical Significance of Molecular Sequence Features by Using General Scoring Schemes, Proceedings of the National Academy of Science, 87(6):2264-2268 (1990).
[cited by applicant]
Katragadda et al., Thermodynamic studies on the interaction of the third complement component and its inhibitor, compstatin, Journal of Biological Chemistry, 279(53): 54987-54995 (2004).
[cited by applicant]
Katragadda et al., Expression of compstatin in
[cited by applicant]
Katragadda et al., Structure-activity-based design of potent compstatin analogs, Molecular Immunology, 44(103): 192 (2007).
[cited by applicant]
Katragadda, M. et al., Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin, Journal of Medicinal Chemistry, 49(15):4616-4622 (2006).
[cited by applicant]
Keam, S. J. et al., Verteporfin, A Review of its Use in the Management of Subfoveal Choroidal Neovascularisation, Drugs, 63: 2521-2554 (2003).
[cited by applicant]
Kent, S., Total Chemical Synthesis of Enzymes, Journal of Peptide Science, 9(9):574-593 (2003).
[cited by applicant]
Klein, RJ et al., Complement Factor H Polymorphism in Age-Related Macular Degeneration, Science, 308(5720):385-389 (2005).
[cited by applicant]
Kohler, G. and Milstein, C., Continuous Cultures of Fused Cells Secreting Antibody of Predetermined Specificity, Nature, 256(5517): 495-497 (1975).
[cited by applicant]
Kourlas, H. et al., Pegaptanib Sodium for the Treatment of Neovascular Age-Related Macular Degeneration: A Review, Clinical Therapeutics, 28(1):36-44 (2006).
[cited by applicant]
Kozlowski, A. et al., Development of Pegylated Interferons for the Treatment of Chronic Hepatitis C, BioDrugs, 15(7):419-429 (2001).
[cited by applicant]
Lamers, C. et al., Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors, Nat Commun., 13(1):5519 (2022).
[cited by applicant]
Lattig-Tunnemann, G. et al., Backbone rigidity and static presentation of guanidinum groups increases cellular uptake or arginine-rich cell-penetrating peptides, Nature Communications, 2:453, 6 pages (2011).
[cited by applicant]
Li, M. et al., CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration, Nature Genetics, 38(9):1049-1054 (2006).
[cited by applicant]
Lippinvott Co., Anti-Vascular Endothelial Growth Factor Therapy for Subfoveal choroidal Neovascularization Secondary to Age-Related Macular Degeneration: Phase II Study Results, Opthal., 110(5): 979-986 (2003).
[cited by applicant]
Liszewski, K. et al., Cleavage of intracellular C3 into C3a and C3b by cathepsin L is required for human TH1 induction, Abstract #61, Immunobiology, 217, p. 1150 (2012).
[cited by applicant]
Liu, D. et al., Suppression of Acute Lung Inflammation by Intracellular Peptide Delivery of a Nuclear Import Inhibitor, The American Society of Gene Therapy, 17(5):796-802 (2009).
[cited by applicant]
Liu, X. Y. et al., Peptide-directed Suppression of a Pro-inflammatory Cytokine Response, The Journal of Biological Chemistry, 275(22):16774-16778 (2000).
[cited by applicant]
Lopes, L. et al., Cell Permeant Peptide Analogues of the Small Heat Shock Protein, HSP20, Reduce TGF-β1-Induced CTGF Expression in Keloid Fibroblasts, Journal of Investigative Dermatology, 129:590-598 (2009).
[cited by applicant]
Magnusson, KP, et al., CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD, PLoS Med, 3:e5 (2006).
[cited by applicant]
Makrides, S.C. et al., Therapeutic inhibition of the complement system, Pharmacological Reviews, 50(1):59-87, American Society for Pharmacology and Experimental Therapeutics, Bethesda, MD (1998).
[cited by applicant]
Maller, J. et al., Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration, Nature Genetics, 38(9):1055-1059 (2006).
[cited by applicant]
Mallik, B et al., Design and NMR characterization of active analogues of compstatin containing non-natural amino acids, Journal of Medicinal Chemistry, 48 (1):274-286 (2005).
[cited by applicant]
Mastellos, D. et al., Compstatin: a C3-targeted complement inhibitor reaching its prime for beside intervention, Eur J. Clin. Invest., 45(4):423-440 (2015).
[cited by applicant]
Mccusker, C. et al., Inhibition of Experimental Allergic Airways Disease by Local Application of a Cell-Penetrating Dominant-Negative STAT-6 Peptide, The Journal of Immunology, 179:2556-2564 (2007).
[cited by applicant]
Michels, S. and Rosenfeld, P.J., Treatment of Neovascular Age-Related Macular Degeneration With Ranibizumab/Lucentis, Klin Monbl Augenheikd, 222(6): 480-484 (2005).
[cited by applicant]
Midena, E., et al., Macular function impairment in eyes with early age-related macular degeneration, Invest. Ophthalmol. Vis. Sci., 38: 467-477 (1997).
[cited by applicant]
Miller, C.G., The Cowpox Virus-Encoded Homolog of the Vaccinia Virus Complement Control Protein Is an Inflammation Modulatory Protein, Virology,229(1):129-133 (1997).
[cited by applicant]
Mishra, Ritu, Biological evaluation of novel peptidic vectors for transmembrane delivery of intracellularly targeted probes for molecular imaging, Dissertation, 103 pages (2009).
[cited by applicant]
Morikis, D. et al., Improvement of the anti-C3 activity of compstatin using rational and combinatorial approaches, Biochemical Society Transactions, 32(1):28-32, Biochemical Society, London, UK (2004).
[cited by applicant]
Morikis, D. et al., Solution structure of Compstatin, a potent complement inhibitor, Protein Science, 7(3):619-627 (1998).
[cited by applicant]
Morikis, D. et al., The Structural Basis of Compstatin Activity Examined by Structure-Function-based Design of Peptide Analogs and NMR, J. Biol. Chem., 277(17):14942-14953 (2002).
[cited by applicant]
Nektar Advanced Pegylation, 34 pages (2005-2006 Product Catalog, Nektar Therapeutics, San Carlos, CA).
[cited by applicant]
Ng et al., Targeting Angiogenesis, the Underlying Disorder in Neovascular Age-Related Macular Degeneration, Canadian Journal of Ophthalmology, 40(3): 352-368 (2005).
[cited by applicant]
Nielsen, M. et al., MHC Class II epitope predictive algorithms, Immunology, 130:319-328 (2010).
[cited by applicant]
No Author Listed, Copper-free Click Chemistry from https://web.archive.org/III0110228014635/http://www.jenabioscience.com/1b94dca880/Newsletter_Copper-Free-ClickChem_Feb11.html, pp. 1-2, published online Feb. 28, 2011.
[cited by applicant]
Novina, C.D. and Sharp, P.A., The RNAi Revolution, Nature, 430(6996): 161-164 (2004).
[cited by applicant]
Nozaki, M. et al., Drusen complement components C3a and C5a promote choroidal neovascularization, Proc. Natl. Acad. Sci. USA, 103:2328-2333 (2006).
[cited by applicant]
Nwe, K. and Brechbiel, M. et al., Growing Applications of “Click Chemistry” for Bioconjugation in Contemporary Biomedical Research, Cancer Biotherapy and Radiopharmaceuticals, 24:289-302 (2009).
[cited by applicant]
Pakula, A. and Sauer, R., Genetic Analysis of Protein Stability and Function, Annu Rev. Genet., 23:289-310 (1989).
[cited by applicant]
Peptide Modifications, Designer Bioscience, created on Jun. 25, 2009, accessed on Jun. 9, 2016, 2 pages.
[cited by applicant]
Pio, R. et al., The Role of Complement in Tumor Growth, C. Koumenis et al. (eds.), Tumor Microenvironment and Cellular Stress, Advances, Experimental Medicine and Biology, 772, Chapter 11, 229-262 (2014).
[cited by applicant]
Rakoczy, P.E. et al., Progressive Age-Related Changes Similar to Age-Related Macular Degeneration in a Transgenic Mouse Model, American Journal of Pathology, 161(4):1515-1524 (2002).
[cited by applicant]
Reid, K.B. and Day, A.J., Structure-Function Relationships of the Complement Components, Immunology Today, 10(6):177-180 (1989).
[cited by applicant]
Ricklin, D. and Lambris, J. Compstatin: a complement inhibitor on its way to clinical application, Adv Exp Med Biol., 632:273-92 (2008).
[cited by applicant]
Ricklin, D. and Lambris, J., Therapeutic control of complement activation at the level of the central component C3, Immunobiology, 221:740-746 (2016).
[cited by applicant]
Ricklin, D. et al., Complement—a key system for immune surveillance and homeostasis, Nat. Immunol., 11(9):785-797 (2010).
[cited by applicant]
Rosenfeld et al., URL: www.revophth.com/index.asp?page+1_857.htm> An Update on Bevacizumab (Dec. 1, 2005).
[cited by applicant]
Rosengard, A.M. et al., Variola Virus Immune Evasion Design: Expression of a Highly Efficient Inhibitor of Human Complement, Proceedings of the National Academy of Science, 99(13):8803-8813 (2002).
[cited by applicant]
Rowe, R.C. et al., Handbook of Pharmaceutical Excipients, Hypromellose, Sorbitol, Handbook of Pharmaceutical Excipients, Pharmaceuticals Press [U.A.], London, pp. 346-349 (2006).
[cited by applicant]
Sahu, A, et al., Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3, Mol. Immunol., 39(10):557-66 (2003).
[cited by applicant]
Sahu, A. et al., Interaction of Vaccinia Virus Complement Control Protein with Human Complement Proteins: Factor I-Mediated Degradation of C3b to iC3b1 Inactivates the Alternative Complement Pathway, Journal of Immunolo…
[cited by applicant]
Sahu, A., et al., Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin, J. Immunol., 165(5):2491-9 (2000).
[cited by applicant]
Sanders, W. et al., Prediction of Cell Penetrating Peptides by Support Vector Machines, PLoS Computational Biology, 7(7):e1002101, 12 pages (2011).
[cited by applicant]
Scullica, L. and Benedetto, F., Diagnosis and classification of macular degenerations: an approach based on retinal function testings, Documenta Ophthalmologica, 102: 237-250 (2001).
[cited by applicant]
Sepp, T. et al., Complement Factor H Variant Y402H Is a Major Risk Determinant for Geographic Atrophy and Choroidal Neovascularization in Smokers and Nonsmokers, Invest. Ophthalmol. Vis. Sci., 47:536-540 (2006).
[cited by applicant]
Siddiqui, M. and Keating, G., Pegaptanib—In Exudative Age-Related Macular Degeneration, Drugs, 65(11):1571-1577 (2005).
[cited by applicant]
Siegmund, T. et al., Comparison of usability and patient preference for insulin pen needles produced with different production techniques: “thin-wall” needles compared to “regular-wall” needles: an open-label study, Dia…
[cited by applicant]
Sivaprasad, S. and Chong, NV. The complement system and age-related macular degeneration, Eye, 20: 867-872 (2006).
[cited by applicant]
Smith, S.S. et al., Conserved Surface-Exposed K/R-X-K/R Motifs and Net Positive Charge on Provirus Complement Control Proteins Serve as Putative Heparin Binding Sites and Contribute to Inhibition of Molecular Interactio…
[cited by applicant]
Soulika, AM, et al., Studies of structure-activity relations of complement inhibitor compstatin, J. Immunol., 171(4):1881-90 (2003).
[cited by applicant]
Soulika, et al., Compstatin Inhibits Complement Activation by Binding to the Beta-Chain of Complement Factor 3, Mol. Immunol., 43:2023-2029 (2006).
[cited by applicant]
Subasinghe, N. et al., Design and synthesis of polyethylene glycol-modified biphenylsulfonyl-thiop-hene-carboxamidine inhibitors of the complement component C1s, Bioorganic & Medicinal Chemistry Letters, 22:5303-5307 (2…
[cited by applicant]
Sugita, T. et al., Comparative study on transduction and toxicity of protein transduction domains, British Journal of Pharmacology, 153:1143-1152 (2008).
[cited by applicant]
Suhorutsenko, J. et al., Cell-Penetrating Peptides, PepFects, Show No Evidence of Toxicity and Immunogenicity in Vitro and In Vivo, Bioconjugate Chemistry, 22:2255-2262 (2011).
[cited by applicant]
Supplemental Partial European Search Report for EP13854990, 6 pages (Jun. 6, 2016).
[cited by applicant]
Tamai, K. et al., Lipid Hydroperoxide Stimulates Subretinal Choroidal Neovascularization in the Rabbit, Experimental Eye Research, 74(2):301-308 (2002).
[cited by applicant]
Tezel, T.H. et al., Pathogenesis of Age-Related Macular Degeneration, TRENDS in Molecular Medicine, 10(9):417-420 (2004).
[cited by applicant]
Torchilin, V.P. et al., p-Nitrophenylcarbonyl-PEG-PE-Liposomes: Fast and Simple Attachment of Specific Ligands, Including Monoclonal Antibodies, to Distal Ends of PEG Chains Via p-Nitrophenylcarbonyl Groups, Biochimica …
[cited by applicant]
Tunnemann, G. et al., Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells, The FASEB Journal, 20:1775-1784 (2006).
[cited by applicant]
Uvarova, E.A. and Shchelkunov, S.N., Species-specific Differences in the Structure of Orthopoxvirus Complement-Binding Protein, Virus Research, 81(1-2):39-45 (2001).
[cited by applicant]
Viegas, T. et al., Polyoxazoline: Chemistry, Properties, and Applications in Drug Delivery, Bioconjugate Chemistry, 22:976-986 (2011).
[cited by applicant]
Walpole, S. et al., The weight of nations: an estimation of adult human biomass, BMC Public Health, 12:439, 6 pages (2012).
[cited by applicant]
Wang, F. et al., AAV-Mediated Expression of Vascular Endothelial Growth Factor Induces Choroidal Neovascularization in Rat, Investigative Ophthalmology and Visual Science, 44(2):781-790 (2003).
[cited by applicant]
Ward, B. et al., Design of a bioactive cell-penetrating, peptide: when a transduction domain does more than transduce, J. Pept. Sci., 15(10):668-674 (2009).
[cited by applicant]
Wender, P. et al., The design, synthesis, and evaluation of molecules that enable or enhance cellular update: Peptoid molecular transporters, PNAS, 97(24):13003-13008 (2000).
[cited by applicant]
Wilson, M. et al., How to Give Intravitreal Injections, Eyenet, pp. 45-47 (2013).
[cited by applicant]
Winter, G. et al., Making Antibody by Phage Display Technology, Annual Reviews in Immunology, 12:433-455 (1994).
[cited by applicant]
Written Opinion for PCT/US05/036547, 7 pages (Jun. 10, 2006).
[cited by applicant]
Written Opinion for PCT/US18/65870 (Dosing Regimens and Related Compositions and Methods, filed Dec. 14, 2018), issued by ISA/US, 16 pages (May 17, 2019).
[cited by applicant]
Written Opinion for PCT/US2007/001649, 9 pages (Mar. 31, 2008).
[cited by applicant]
Written Opinion for PCT/US2012/037648, (Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof, filed May 11, 2012) issued by ISA, 7 pages (received Sep. 20, 2012).
[cited by applicant]